ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 60 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $271,000 | +45.7% | 132,385 | +104.9% | 0.00% | – |
Q4 2021 | $186,000 | -32.1% | 64,623 | 0.0% | 0.00% | – |
Q3 2021 | $274,000 | -2.8% | 64,623 | +21.2% | 0.00% | – |
Q2 2021 | $282,000 | +10.6% | 53,312 | -2.8% | 0.00% | – |
Q1 2021 | $255,000 | +40.9% | 54,866 | 0.0% | 0.00% | – |
Q4 2020 | $181,000 | -0.5% | 54,866 | 0.0% | 0.00% | – |
Q3 2020 | $182,000 | -1.6% | 54,866 | 0.0% | 0.00% | – |
Q2 2020 | $185,000 | -23.9% | 54,866 | -13.4% | 0.00% | – |
Q1 2020 | $243,000 | -26.6% | 63,328 | +15.4% | 0.00% | – |
Q4 2019 | $331,000 | -21.7% | 54,866 | -1.9% | 0.00% | – |
Q3 2019 | $423,000 | -44.2% | 55,943 | 0.0% | 0.00% | – |
Q2 2019 | $758,000 | +150.2% | 55,943 | 0.0% | 0.00% | – |
Q1 2019 | $303,000 | +82.5% | 55,943 | 0.0% | 0.00% | – |
Q4 2018 | $166,000 | -67.5% | 55,943 | -10.7% | 0.00% | – |
Q3 2018 | $511,000 | -16.2% | 62,670 | 0.0% | 0.00% | – |
Q2 2018 | $610,000 | +24.2% | 62,670 | +11.0% | 0.00% | – |
Q1 2018 | $491,000 | -30.6% | 56,475 | 0.0% | 0.00% | – |
Q4 2017 | $707,000 | – | 56,475 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 507,191 | $5,107,000 | 0.50% |
Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |